Antidepressant-like Activity of a Triple Combination of Venlafaxine, Codeine and Nor-Binaltorphimine in the Mouse Tail Suspension Test
4 affiliations
- 1Department No. 14 of Orthopedics, Anesthesia and Intensive Care, Faculty of Medicine, “Carol Davila” University of Medicine and Pharmacy, 050474 Bucharest, Romania
- 2Department III Functional Sciences, Discipline of Medical Informatics and Biostatistics, “Victor Babeș” University of Medicine and Pharmacy, 300041 Timișoara, Romania
- 3Department of Pharmacology, Clinical Pharmacology and Pharmacotherapy, Faculty of Medicine, “Carol Davila” University of Medicine and Pharmacy, 050474 Bucharest, Romania
- 4Doctoral School, “Carol Davila” University of Medicine and Pharmacy, 020021 Bucharest, Romania
Abstract
About one-third of patients with major depressive disorder do not remit on conventional monoaminergic antidepressants. Venlafaxine (VEN) is a classic antidepressant that inhibits serotonin and norepinephrine reuptake. Venlafaxine does not bind opioid receptors, yet its antidepressant-like action requires intact µ-opioid signalling. The dynorphin/κ-opioid axis exerts an opposing, dysphoria-promoting influence. A possible question is whether combining serotonin and noradrenaline reuptake inhibition, µ-opioid receptor activation by codeine (COD) and sustained κ-opioid receptor blockade produces an antidepressant-like effect larger than that of the components given alone. Male NMRI mice were tested in the forced swim test (FST) (one experiment) and in the tail suspension test (TST) (three experiments) using a parallel-design (n = 10 to 17 per group; 277 animals), as follows: VEN 10 to 40 mg/kg in both tests—FST and TST; COD 10 to 40 mg/kg added to VEN 20 mg/kg in TST; and nor-binaltorphimine (norBNI) 10 mg/kg, given 24 h before, combined with VEN 20 mg/kg and COD 20 mg/kg and compared with norBNI alone, COD alone and norBNI + VEN, with amitriptyline (AMI) 20 mg/kg as the positive control in the TST. The three agents and two reference ligands were also docked into eight experimental human structures of the monoamine transporters and of the μ, κ and δ opioid receptors. VEN did not reduce FST immobility at any dose but produced a dose-dependent reduction in the TST, reaching −66.2% at 40 mg/kg. COD did not potentiate VEN 20 mg/kg at any of three COD doses. The triple combination, in the TST, reduced immobility by 65.7% relative to saline (Dunnett p = 0.013), an effect of similar magnitude to AMI with no significant difference detected between them, whereas norBNI alone, COD alone and norBNI + VEN did not reach significance. The design was underpowered for intermediate effects (the calculated n should be about 36 per group, unapproved because of ethical considerations). The triple combination was not significantly more effective than norBNI + VEN (p = 0.375), so the contribution of codeine remains undetermined. Docking reproduced the experimental pose of all eight co-crystallised ligands and was consistent with VEN occupying the transporter S1 site, COD the μ-opioid pocket and norBNI the κ receptor. A triple serotonin-adrenergic and opioid combination produced an antidepressant-like effect that none of the single treatments tested in the same cohort reached, but the fixed-dose design does not establish cooperativity between all three mechanisms. The docking results are consistent with, but do not prove, engagement of three separate sites.
Related
- Transcriptional Reprogramming in Prostate Cancer: Altered AR Activity, the Modulatory Role of CDK8/19, and Prospects for Combination Therapy
- Safety and Antitumor Activity of the Usnic Acid Derivative OL9-116, a TDP1 Inhibitor, as an Adjunctive Therapy in Combination with Topotecan
- A Redox-Switchable Supramolecular Carbohydrate Chip for Capture and Real-Time Glycosylation Analysis of Living Suspension Cells
- Culture medium and plant growth regulator regimes influence the transcriptome and cannabisin accumulation in Cannabis sativa cell suspension cultures
- HDAC inhibitors in cancer therapy: sensitization mechanisms, combination strategies, and translational challenges
BibTeX
@article{lungu2026antidepressantlike,
title = {{Antidepressant-like Activity of a Triple Combination of Venlafaxine, Codeine and Nor-Binaltorphimine in the Mouse Tail Suspension Test}},
author = {Cristina Lungu and Călin Muntean and Horia Păunescu and Ruxandra-Cristina Marin and Florin-Adrian Lungu and Mihnea Costescu and Cristina Isabel Viorica Ghiță and Ion Fulga and Oana Andreia Coman},
journal = {International Journal of Molecular Sciences},
year = {2026},
month = oct,
doi = {10.3390/ijms27219719},
url = {https://www.mdpi.com/1422-0067/27/21/9719},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Antidepressant-like Activity of a Triple Combination of Venlafaxine, Codeine and Nor-Binaltorphimine in the Mouse Tail Suspension Test
AU - Cristina Lungu
AU - Călin Muntean
AU - Horia Păunescu
AU - Ruxandra-Cristina Marin
AU - Florin-Adrian Lungu
AU - Mihnea Costescu
AU - Cristina Isabel Viorica Ghiță
AU - Ion Fulga
AU - Oana Andreia Coman
PY - 2026
DA - 2026/10/29
JO - International Journal of Molecular Sciences
DO - 10.3390/ijms27219719
UR - https://www.mdpi.com/1422-0067/27/21/9719
AB - About one-third of patients with major depressive disorder do not remit on conventional monoaminergic antidepressants. Venlafaxine (VEN) is a classic antidepressant that inhibits serotonin and norepinephrine reuptake. Venlafaxine does not bind opioid receptors, yet its antidepressant-like action requires intact µ-opioid signalling. The dynorphin/κ-opioid axis exerts an opposing, dysphoria-promoting influence. A possible question is whether combining serotonin and noradrenaline reuptake inhibition, µ-opioid receptor activation by codeine (COD) and sustained κ-opioid receptor blockade produces an antidepressant-like effect larger than that of the components given alone. Male NMRI mice were tested in the forced swim test (FST) (one experiment) and in the tail suspension test (TST) (three experiments) using a parallel-design (n = 10 to 17 per group; 277 animals), as follows: VEN 10 to 40 mg/kg in both tests—FST and TST; COD 10 to 40 mg/kg added to VEN 20 mg/kg in TST; and nor-binaltorphimine (norBNI) 10 mg/kg, given 24 h before, combined with VEN 20 mg/kg and COD 20 mg/kg and compared with norBNI alone, COD alone and norBNI + VEN, with amitriptyline (AMI) 20 mg/kg as the positive control in the TST. The three agents and two reference ligands were also docked into eight experimental human structures of the monoamine transporters and of the μ, κ and δ opioid receptors. VEN did not reduce FST immobility at any dose but produced a dose-dependent reduction in the TST, reaching −66.2% at 40 mg/kg. COD did not potentiate VEN 20 mg/kg at any of three COD doses. The triple combination, in the TST, reduced immobility by 65.7% relative to saline (Dunnett p = 0.013), an effect of similar magnitude to AMI with no significant difference detected between them, whereas norBNI alone, COD alone and norBNI + VEN did not reach significance. The design was underpowered for intermediate effects (the calculated n should be about 36 per group, unapproved because of ethical considerations). The triple combination was not significantly more effective than norBNI + VEN (p = 0.375), so the contribution of codeine remains undetermined. Docking reproduced the experimental pose of all eight co-crystallised ligands and was consistent with VEN occupying the transporter S1 site, COD the μ-opioid pocket and norBNI the κ receptor. A triple serotonin-adrenergic and opioid combination produced an antidepressant-like effect that none of the single treatments tested in the same cohort reached, but the fixed-dose design does not establish cooperativity between all three mechanisms. The docking results are consistent with, but do not prove, engagement of three separate sites.
SN - 1422-0067
ER -